Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds

Anticancer Research

Volumn 18, Issue 4 C, 1998, Pages 3033-3038

  Molnár, Joseph ^a   Szabo, Diana ^a   Mándi, Yvette ^a   Mucsi, Ilona ^a   Fischer, János ^a   Varga, Andreas ^b   König, Sigrid ^b   Motohashi, Noboru ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Blood brain barrier; Multidrug resistance; Phenothiazines; Tomato lectin

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; FLUOROURACIL; GLYCOPROTEIN P; HETEROCYCLIC COMPOUND; LECTIN; METHOTREXATE; MITOXANTRONE; PHENOTHIAZINE DERIVATIVE; PROMETHAZINE; RESERPINE; TRIFLUOPERAZINE; VERAPAMIL; VINCA ALKALOID; YOHIMBINE;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CANCER CELL CULTURE; CAPILLARY ENDOTHELIUM; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSFECTION; LYMPHOMA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FLUORESCENT DYES; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, T-CELL; MICE; P-GLYCOPROTEIN; RHODAMINE 123; RHODAMINES;

EID: 0031839228     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Endicott JA and Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58: 137-171, 1989.
2. Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SPC and Kuwano M: Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Brit J Cancer 71: 907-913, 1995.
3. Zaman GJR, Flens MJ, van Leusden M-R, de Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ and Borst P: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822-8826, 1994.
4. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen THM, van Kalken CK, Slovak ML, de Vries EGE, van der Valk P, Meijer CJLM and Pinedo HM: Overepression of a Mdr 110,000 versicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-1479, 1 993.
5. Whelan RDH, Hosking LK, Townsend AJ, Cowan KH and Hill BT: Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines. Cancer Commun 1: 359-365, 1989.
6. Kellner U, Hutchinson L, Seidel A, Lage H, Danks MK, Dietel M and Kaufmann SH: Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int J Cancer 71: 817-824, 1997.
7. Molnar J, Hever A, Fakla I, Fischer J, Ocsovszki I and Aszalos A: Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells. Anticancer Res 17: 481-486, 1997.
8. Motohahsi N, Kawase M, Kurihara T, Hever A, Nagy Sz, Ocsovszki I, Tanaka M and Molnar J: Synthesis and antitumor activity of 1-(2-chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkylureas as potential anticancer agents. Anticancer Res 16: 2525-2532, 1996.
9. Aszalos A and Eckhardt S: Molecular events as targets of anticancer drug therapy. Pathology Oncology Res 3 (No2): 147-158, 1 997.
10. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE and Paull KD: An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349, 1997.
11. Motohashi N, Kurihara.T, Kawase M, Hever A, Tanaka M, Szabo D, Nacsa J, Yamanaka W, Kerim A and Molnar J: Drug resistance reversal, anti-mutagenicity and antiretroviral effect of phthalimido-and chloroethyl-phenothiazines. Anticance! Res 17: 3537-3543, 1997.
12. Wuonola MA, Palfreyman MG, Motohashi N, Kawase M, Gabay S, Nacsa J and Molnar J: The primary in vitro antitumor screening of "half-mustard type" phenothiazines. Anticancer Res 17: 3409-3423, 1997.
13. Molnar J, Szabo D, Csuri K, Kurihara T and Motohashi N: Possible correlation between chemical structure and tumor type specificity of phenothiazine derivatives or half-mustard type of phenothiazines. Anticancer Res 18: in preparation, 1998.
14. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62: 385-427, 1993.
15. Andreana A, Gollapudi S and Gupta S: Salmonella typhimurium induces expression of P glycoprotein (multidrug resistance 1 gene product) in a promonocytic cell line chronically infected with human immunodeficiency virus type 1. J Infect Dis 169: 760-765, 1994.
16. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li X and Nishino T: Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 21: 713-724, 1996.
17. Matthysse AG, Yarnall HA and Young N: Requirement for genes with homology to ABC transport systems for attachment and virulence of Agrobacterium tumefaciens. J Bacteriol 178: 5302-5308, 1996.
18. Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL and Ling V: Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324: 485-489, 1986.
19. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M and Bille J: Mechanisms of resistance to azole antifungal agents in Candida albicans isolated from AIDS patients involve specific multidrug transporters. Antimicro Agents Chemother 39: 2378-2386, 1995.
20. Broeks A, Gerrard B, Allikmets R, Dean M and Plasterk RHA: Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode Caenorhabditis elegans. EMBO J 15: 6132-6143, 1 996.
21. Hegewisch-Becker S, Fliegener M, Tsuruo T, Zeller W and Hossfeld DK: Multidrug resistance (mdr 1) in adult acute leukemia at diagnosis: correlation with response to induction chemotherapy. Onkologie 16: 264-269, 1993.
22. Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Nakazima Y and Akiyama S: Glycosylatin of P-glycoprotein in a multidrug-resistant KB cell line, and in the human tissues. Biochim Biophy Acta 1073: 309-315, 1991.
23. Motohashi N: Test for antitumor activities of phenothiazines and phenoxazines. (in Japanese). Yakugaku Zasshi 103: 364-371, 1 983.
24. Hewlett I, Lee S, Molnar J, Foldeak S, Pine PS, Weaver JL and Aszalos A: Inhibition of HIV infection of H9 cells by chlorpromazine derivatives. J Acquired Immun Deficiency Syndrom Human Retrovirol 15: 16-20, 1997.
25. Cornwell MM, Pastan I and Gottesman MM: Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262: 2166-2170, 1 987 .
26. Stein U, Walther W and Shoemaker H: Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Nat Cancer Inst 88: 1383-1392, 1 996.
27. (a) Palfreyman MG, Wuonola M, Motohashi N, Kawase M, Gabay S, Gupta RR and Molnar J: The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCl's revised anticancer screening paradigm. Anticancer Res 17: in press, 1997.
28. (b) Palfreyman MG, Wuonola M, Motohashi N, Kawase M, Gabay S and Molnar J: Phenothiazine compounds, compositions and methods of using the same. U.S. Patent in press, 1998.
29. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA and Hiestand PC: Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 51: 433-438, 1992.
30. Szabó D and Molnár J: The role stereoselectivity of chemosensitizers in the reversal of multidrug-resistance of mouse lymphoma. In preparation for Anticancer Res 18: 1998.
31. Molnár J, Mándi Y, Hever A, Ocsovszky I, Földeák S, Schneider J, Emody L and Aszalos A: Reversal of drug resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 51: 433-438, 1992.
32. Molnár J, Mándi Y, Hevér A, Ocsovszky i, Földeák S, Schneider J, Emody L and Aszalos A: Reversal of drug resistance in bacteria and tumor cells by some substituted phenothiazines. Anticancer Res 15: 1648, 1995.